SNY:NYE-Sanofi American Depositary Shares (Each repstg one-half of one)

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 44.91

Change

+0.13 (+0.29)%

Market Cap

USD 113.03B

Volume

2.66M

Yahoo Analyst Target

USD 49.50 (10.22%)

STA Analyst Target

USD 51.67 (15.04%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing SNY

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.44% 52% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.44% 52% F 72% C-
Trailing 12 Months  
Capital Gain 8.30% 43% F 52% F
Dividend Return 3.80% 76% C 56% F
Total Return 12.10% 43% F 52% F
Trailing 5 Years  
Capital Gain -6.42% 28% F 33% F
Dividend Return 17.82% 40% F 54% F
Total Return 11.40% 22% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -1.60% 30% F 23% F
Dividend Return 1.99% 30% F 25% F
Total Return 3.59% 82% B- 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 13.96% 83% B 54% F
Risk Adjusted Return 14.23% 35% F 24% F
Market Capitalization 100.27B 77% C+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.70 78% C+ 66% D
Price/Book Ratio 1.89 83% B 53% F
Price / Cash Flow Ratio 3.16 70% C- 44% F
Price/Free Cash Flow Ratio 15.02 78% C+ 45% F
Management Effectiveness  
Return on Equity 33.37% 83% B 92% A-
Return on Invested Capital 19.95% 83% B 85% B
Return on Assets 18.30% 100% A+ 97% A+
Debt to Equity Ratio 16.00% 91% A- 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector